1. Home
  2. HYFT vs ACET Comparison

HYFT vs ACET Comparison

Compare HYFT & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HYFT

MindWalk Holdings Corp.

N/A

Current Price

$1.31

Market Cap

69.6M

Sector

Health Care

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

N/A

Current Price

$7.54

Market Cap

69.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HYFT
ACET
Founded
1983
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.6M
69.6M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
HYFT
ACET
Price
$1.31
$7.54
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$65.33
AVG Volume (30 Days)
312.6K
161.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
59.82
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$51.71
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.05
$0.45
52 Week High
$3.00
$9.05

Technical Indicators

Market Signals
Indicator
HYFT
ACET
Relative Strength Index (RSI) 46.21 55.37
Support Level N/A $6.54
Resistance Level $2.17 $8.46
Average True Range (ATR) 0.09 0.47
MACD 0.02 -0.00
Stochastic Oscillator 66.25 61.05

Price Performance

Historical Comparison
HYFT
ACET

About HYFT MindWalk Holdings Corp.

MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: